BCMA CHIMERIC ANTIGEN RECEPTORS
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
6 Citations
86 Claims
-
1-65. -65. (canceled)
-
66. A population of cells comprising T cells, wherein the T cells comprise a lentiviral vector comprising a left (5′
- ) lentiviral LTR, a Psi (Ψ
) packaging signal, a central polypurine tract/DNA flap (cPPT/FLAP), a retroviral export element;
a promoter operably linked to the polynucleotide sequence set forth in SEQ ID NO;
10; and
a right (3′
) lentiviral LTR - View Dependent Claims (67, 68, 69, 70, 71, 72, 73, 74, 75, 76)
- ) lentiviral LTR, a Psi (Ψ
-
77. A population of cells comprising immune effector cells, wherein the immune effector cells comprise a lentiviral vector, wherein the lentiviral vector comprises a left (5′
- ) lentiviral LTR wherein the promoter of the 5′
LTR is replaced with a CMV promoter;
a Psi (Ψ
) packaging signal, a cPPT/FLAP, an RRE Rev response element;
a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to the polynucleotide sequence set forth in SEQ ID NO;
10;
a right (3′
) lentiviral SIN LTR; and
a heterologous polyadenylation sequence. - View Dependent Claims (78, 79, 80, 81, 82, 83, 84, 85, 86)
- ) lentiviral LTR wherein the promoter of the 5′
Specification